Finanzen von Icecure Medical Ltd (ICCM)ICCMIcecure Medical Ltd

Evaluating the bottom line, Icecure Medical Ltd maintains a gross margin of 27.89%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -487.76%, while the net margin is -496.25%. These profitability ratios, combined with a Return on Equity (ROE) of -228.31%, provide a clear picture of how effectively ICCM converts its operational activities into shareholder value.

In the context of the broader market, ICCM competes directly with industry leaders such as NUWE and BRTX. With a market capitalization of $2.33M, it holds a leading position in the sector. When comparing efficiency, ICCM's gross margin of 27.89% stands against NUWE's 76.08% and BRTX's 68.13%. Such benchmarking helps identify whether Icecure Medical Ltd is trading at a premium or discount relative to its financial performance.

Icecure Medical has shown significant revenue growth of 45% year-over-year in H1 2026, with total revenue reaching $1.8 million. However, the company continues to experience substantial net losses, with a net loss of $8.8 million in H1 2026, reflecting ongoing operational challenges despite revenue growth.